Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Whoosh reported for 2022 according to IFRS

4/26/23 WUSH

Microsoft reported for 9 months of fiscal year 2023

4/26/23 MSFT

Visa reported for 6 months of fiscal year 2023

4/26/23 V

Alphabet reported for 3 months of 2023

4/26/23 GOOG

Uniper's stake in Unipro transferred to Rosimuschestvo for temporary management

4/26/23 UPRO

TMK's RAS profit nearly doubled in 2022

4/26/23 TRMK

Rosimushchestvo received Fortum's stake in TGC-1 under temporary management

4/25/23 TGKA

Genetico completes IPO offering

4/25/23 GECO

The International Business Machines announced a quarterly dividend

4/25/23 IBM

Tatneft may participate in modernization of Bukhara refinery in Uzbekistan

4/25/23 TATN